GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » ROA %

Rakovina Therapeutics (TSXV:RKV) ROA % : -70.46% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Rakovina Therapeutics's annualized Net Income for the quarter that ended in Sep. 2024 was C$-4.06 Mil. Rakovina Therapeutics's average Total Assets over the quarter that ended in Sep. 2024 was C$5.77 Mil. Therefore, Rakovina Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -70.46%.

The historical rank and industry rank for Rakovina Therapeutics's ROA % or its related term are showing as below:

TSXV:RKV' s ROA % Range Over the Past 10 Years
Min: -63.77   Med: -46.38   Max: -37.77
Current: -61.07

During the past 3 years, Rakovina Therapeutics's highest ROA % was -37.77%. The lowest was -63.77%. And the median was -46.38%.

TSXV:RKV's ROA % is ranked worse than
69% of 1500 companies
in the Biotechnology industry
Industry Median: -34.715 vs TSXV:RKV: -61.07

Rakovina Therapeutics ROA % Historical Data

The historical data trend for Rakovina Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics ROA % Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROA %
-63.77 -37.77 -46.38

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.38 -52.72 -61.66 -60.62 -70.46

Competitive Comparison of Rakovina Therapeutics's ROA %

For the Biotechnology subindustry, Rakovina Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's ROA % falls into.



Rakovina Therapeutics ROA % Calculation

Rakovina Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-2.613/( (6.121+5.148)/ 2 )
=-2.613/5.6345
=-46.38 %

Rakovina Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-4.064/( (6.227+5.308)/ 2 )
=-4.064/5.7675
=-70.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Rakovina Therapeutics  (TSXV:RKV) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-4.064/5.7675
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.064 / 0)*(0 / 5.7675)
=Net Margin %*Asset Turnover
=N/A %*0
=-70.46 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Rakovina Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.
Executives
Alfredo De Lucrezia Director, Senior Officer
Michael Liggett Director
Jeffrey Bacha Senior Officer
Mads Daugaard Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines